Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,296 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Serum high-mobility group box 1 as a predictive marker for cytotoxic chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease.
Nakao S, Yamaguchi K, Iwamoto H, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H, Hattori N. Nakao S, et al. Among authors: miyamoto s. Respir Med. 2020 Oct;172:106131. doi: 10.1016/j.rmed.2020.106131. Epub 2020 Aug 28. Respir Med. 2020. PMID: 32911136 Free article.
Alternate-day administration of S-1 for elderly patients with advanced non-small-cell lung carcinoma: A prospective feasibility study.
Masuda T, Watanabe M, Fujitaka K, Hamai K, Ishikawa N, Doi M, Kitaguchi S, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Nakashima T, Senoo T, Iwamoto H, Hamada H, Hattori N. Masuda T, et al. Among authors: miyamoto s. Mol Clin Oncol. 2018 Nov;9(5):539-544. doi: 10.3892/mco.2018.1705. Epub 2018 Aug 24. Mol Clin Oncol. 2018. PMID: 30345049 Free PMC article.
Clinical significance of BIM deletion polymorphism in chemoradiotherapy for non-small cell lung cancer.
Wakabayashi Y, Masuda T, Fujitaka K, Nakashima T, Okumoto J, Shimoji K, Nishimura Y, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Iwamoto H, Ohshimo S, Hamada H, Hattori N. Wakabayashi Y, et al. Among authors: miyamoto s. Cancer Sci. 2021 Jan;112(1):369-379. doi: 10.1111/cas.14711. Epub 2020 Nov 12. Cancer Sci. 2021. PMID: 33103296 Free PMC article.
Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer.
Nakanishi Y, Masuda T, Yamaguchi K, Sakamoto S, Horimasu Y, Nakashima T, Miyamoto S, Tsutani Y, Iwamoto H, Fujitaka K, Miyata Y, Hamada H, Okada M, Hattori N. Nakanishi Y, et al. Among authors: miyamoto s. Respir Investig. 2019 Sep;57(5):451-459. doi: 10.1016/j.resinv.2019.05.002. Epub 2019 Jun 24. Respir Investig. 2019. PMID: 31248832
Extent of pulmonary fibrosis on high-resolution computed tomography is a prognostic factor in patients with pleuroparenchymal fibroelastosis.
Namba M, Masuda T, Takao S, Terada H, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Nakashima T, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Awai K, Hattori N. Namba M, et al. Among authors: miyamoto s. Respir Investig. 2020 Nov;58(6):465-472. doi: 10.1016/j.resinv.2020.05.009. Epub 2020 Aug 3. Respir Investig. 2020. PMID: 32762953
Serial measurements of KL-6 for monitoring activity and recurrence of interstitial pneumonia with anti-aminoacyl-tRNA synthetase antibody: A retrospective cohort study.
Yamaguchi K, Iwamoto H, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Ohshimo S, Fujitaka K, Hamada H, Kohno N, Hattori N. Yamaguchi K, et al. Among authors: miyamoto s. Medicine (Baltimore). 2018 Dec;97(49):e13542. doi: 10.1097/MD.0000000000013542. Medicine (Baltimore). 2018. PMID: 30544464 Free PMC article.
3,296 results